Trimebutine
Phase 2Small molecule
Trimebutine is one of 39 small molecule programs targeting Hemorrhoid. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Botox
GGalderma R&D
Approved
Marcaine
IInnocoll
Approved
Ketalar
AAultman Health Foundation
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Celestone
SSchering-Plough
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome1 trial
Abdominal pain1 trial
Helicobacter Pylori Eradication1 trial
Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications
Completed·—·Phase 4·NCT04403087·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trimebutine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMansoura University